FolioLanternBeta
ODTXOdyssey Therapeutics, Inc. · Insider ownership research

Odyssey Therapeutics, Inc. insiders: what they own and what they did with it

None of it through sales. No officer or director reported an open-market sale in this period.

Updated Oct 13, 2026 from SEC filings · covers Oct 14, 2025 to Oct 13, 2026
2
buyers among officers and directors (2 trades), past 12 months
0 of 13
officers and directors sold shares, past 12 months
Latest filing: Filed May 11 for a transaction on May 11. Shelley Chu reported a change in holdings. Filing
SEC ownership filings: 34 filed in the 12 months to Oct 13, 2026; 34 on record since May 7, 2026 · See the evidence

What stands out

Two insiders bought shares: Jeffrey Leiden (5K shares, $100K) and Jason Haas (1K shares, $20K). These are the first purchases by current officers or directors in the filings on record.Jeffrey Leiden: purchase, May 8, 2026 · Jason Haas: purchase, May 8, 2026
Tax withholding outweighed market sales: the company withheld $378 of officers' and directors' shares for taxes, against $0 sold on the open market. The largest was Jeffrey Leiden ($306 withheld).Largest withholding, May 11, 2026

No officer or director sold shares in this period. 13 are left out

i
Left out: Gary Glick, Jeffrey Leiden, Ian Smith, Jason Haas, Natalie Dales, Carolyn Ng, Collin Todd, Jolie Siegel, Anthony Opipari, Shelley Chu, Ourania Tatsis, Valerie Odegard and Timothy Walbert (share of stake is being verified).
Disclosed company stock is not an insider's whole wealth.

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

May 11, 20262 insiders had 21 shares ($378) withheld by the company for taxes (not a market sale). 3.5K shares came in from vesting or option exercises the same day, so their combined holdings rose by 39K net.
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Jeffrey Leiden
Director
17$18.00n/an/aMay 11, 2026May 11, 2026
Anthony Opipari
Interim Chief Medical Officer and Executive Vice President, Translational Medicine
4$18.00n/an/aMay 11, 2026May 11, 2026

Outside holders, reported separately

SR ONE CAPITAL MANAGEMENT, LLC sold $32K in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Odyssey Therapeutics, Inc. CEO selling stock?

No. Gary Glick reported no open-market sales in the past 12 months.

Are any Odyssey Therapeutics, Inc. insiders buying?

Yes. 2 officers or directors reported 2 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold0 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan

Board members representing outside shareholders, reported separately: Nan Li. Details

Outside holder, reported separately: Dimension Capital II, L.P. (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: TPG GP A, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: SR ONE CAPITAL MANAGEMENT, LLC (a 10% owner, not part of management). Sold $32K (1.8K shares) from May 11, 2026 to May 11, 2026. Latest filing

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Gary Glick
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Gary Glick are complete.
President and Chief Executive Officer, Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Gary Glick

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gary Glick are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
128,771$3.98Dec 9, 2031$1.8M
13,376$3.98Jun 29, 2032$188K
372,353$3.98Mar 6, 2034$5.2M
941,429$4.18Sep 9, 2035$13.0M
313,809$4.18Sep 9, 2035$4.3M
884,450$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Jeffrey Leiden
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jeffrey Leiden are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Jeffrey Leiden

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Leiden are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
−17withheld by the company for taxes

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,599$3.98Jun 29, 2032$36K
6,843$3.98Jun 29, 2032$96K
280$3.98Sep 29, 2032$4K
78,681$3.98Mar 6, 2034$1.1M
25,643$3.98Dec 17, 2034$360K
209,594$4.18Sep 9, 2035$2.9M
626,220$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Ian Smith
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ian Smith are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Ian Smith

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ian Smith are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
27,393$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Jason Haas
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jason Haas are complete.
Chief Financial Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Jason Haas

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jason Haas are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
128,215$3.98Dec 17, 2034$1.8M
112,281$4.18Sep 9, 2035$1.6M
43,817$4.18Sep 9, 2035$606K

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Natalie Dales
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Natalie Dales are complete.
Chief of Research Operations and Portfolio Strategy
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Natalie Dales

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Natalie Dales are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
4,828$3.98Mar 6, 2034$68K
40,655$4.18Sep 9, 2035$562K
79,773$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Carolyn Ng
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Carolyn Ng are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Carolyn Ng

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carolyn Ng are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
Collin Todd
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Collin Todd are complete.
Senior Vice President, Strategy and Business Development
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Collin Todd

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Collin Todd are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
15,257$3.98Jun 29, 2032$214K
7,628$3.98Dec 15, 2032$107K
11,400$3.98Mar 6, 2034$160K
5,145$3.98Jun 3, 2034$72K
20,582$3.98Dec 12, 2034$289K
46,147$4.18Sep 9, 2035$638K
15,382$4.18Sep 9, 2035$213K
57,939$4.18Dec 29, 2035$801K
93,904$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Jolie Siegel
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jolie Siegel are complete.
Executive Vice President, General Counsel and Secretary
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Jolie Siegel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jolie Siegel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
78,958$5.15Mar 11, 2036$1.0M

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Anthony Opipari
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Anthony Opipari are complete.
Interim Chief Medical Officer and Executive Vice President, Translational Medicine
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Anthony Opipari

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Anthony Opipari are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
−4withheld by the company for taxes

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
9,335$3.98Oct 6, 2031$131K
9,570$3.98Dec 16, 2031$134K
2,058$3.98Dec 9, 2031$29K
9,716$3.98Mar 6, 2034$136K
13,314$4.18Sep 9, 2035$184K
39,943$4.18Sep 9, 2035$552K
250,203$18.00May 6, 2036$0
27,777$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Shelley Chu
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Shelley Chu are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Shelley Chu

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shelley Chu are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
Ourania Tatsis
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ourania Tatsis are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Ourania Tatsis

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ourania Tatsis are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
196,497$4.18Sep 18, 2035$2.7M
27,393$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Valerie Odegard
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Valerie Odegard are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Valerie Odegard

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Valerie Odegard are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
15,038$3.98Oct 6, 2031$211K
8,839$3.98Dec 16, 2031$124K
27,308$4.18Sep 9, 2035$377K
9,102$4.18Sep 9, 2035$126K
54,029$4.18Dec 3, 2035$747K
18,009$4.18Dec 3, 2035$249K
64,168$5.15Mar 11, 2036$825K
27,393$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Timothy Walbert
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Timothy Walbert are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Timothy Walbert

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Timothy Walbert are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
97,024$3.98Nov 3, 2034$1.4M
74,604$4.18Sep 9, 2035$1.0M
24,868$4.18Sep 9, 2035$344K
27,393$18.00May 6, 2036$0

Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (May 11, 2026), not a market close.

Holdings and share of stake for Odyssey Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board memberHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Nan Li
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Nan Li are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Nan Li

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nan Li are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Odyssey Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology34 filings on record, 34 filed in the 12-month period, and how we read them

All 34 Forms 3, 4 and 5 on record for Odyssey Therapeutics, Inc. (SEC CIK 1882782), filed from May 7, 2026 to May 13, 2026; 34 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (2)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
Aranicki PavleticNo balance on record
Paulina HillNo balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.